- EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
- EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
- EQS-DD: Eckert & Ziegler Strahlen- und Medizintechnik AG: Dr. Hakim Bouterfa, buy
- EQS-DD: Eckert & Ziegler Strahlen- und Medizintechnik AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, buy
- EQS-News: Change in the Supervisory Board of Eckert & Ziegler AG
- EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler
- EQS-PVR: Eckert & Ziegler Strahlen- und Medizintechnik AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-DD: Eckert & Ziegler Strahlen- und Medizintechnik AG: Prof. Dr. Wolfgang Maennig, buy
- EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
More ▼
Key statistics
On Friday, Eckert & Ziegler Strahlen und Medizintechnik AG (EUZX:GER) closed at 56.25, -29.69% below its 52-week high of 80.00, set on Feb 03, 2022.
52-week range
Markit short selling activity
Open | 55.00 |
---|---|
High | 56.25 |
Low | 53.95 |
Bid | 55.85 |
Offer | 55.95 |
Previous close | 55.40 |
Average volume | 48.66k |
---|---|
Shares outstanding | 21.17m |
Free float | 14.61m |
P/E (TTM) | 40.99 |
Market cap | 1.19bn EUR |
EPS (TTM) | 1.37 EUR |
Annual div (ADY) | 0.50 EUR |
---|---|
Annual div yield (ADY) | 0.89% |
Div ex-date | Jun 02 2022 |
Div pay-date | Jun 06 2022 |
Data delayed at least 15 minutes, as of Feb 03 2023 16:35 GMT.
More ▼